Cancer immunotherapy comes of age.
Cancer immunotherapy comes of age.
复制标题
DOI：
10.1038/nature10673
复制
发表时间：
2011-12-21
期刊：
影响因子：
64.8
通讯作者：
Dranoff, Glenn
中科院分区：
文献类型：
--
作者：
Mellman, Ira;Coukos, George;Dranoff, Glenn
长期以来，激活免疫系统以治疗癌症一直是一些免疫学家甚至一些肿瘤学家的梦想。经过几十年的失望，由于最近概念验证临床试验的成功，潮流终于改变了。最值得注意的是抗CTLA4抗体ipilimumab能够显著提高转移性黑色素瘤患者的生存率，这是常规治疗失败的指征。在理解耐受性、免疫性和免疫抑制如何调节抗肿瘤免疫应答以及靶向治疗出现的背景下，这些成功表明主动免疫治疗代表了一条在癌症患者中获得持久、持久应答的途径。
Activating the immune system for therapeutic benefit in cancer has long been a dream of some immunologists, and even a few oncologists. After decades of disappointment, the tide has finally changed due to the success of recent proof-of-concept clinical trials. Most notable has been the ability of the anti-CTLA4 antibody ipilimumab to achieve significant increases in survival of patients with metastatic melanoma, an indication where conventional therapies have failed. Viewed in the context of advances in understanding of how tolerance, immunity, and immunosuppression regulate anti-tumor immune responses together with the advent of targeted therapies, these successes suggest that active immunotherapy represents a path forward to obtaining durable, long-lasting responses in cancer patients.
登录
查看更多内容
影响因子：
4.4
作者：
Bouzin, Caroline;Brouet, Agnes;Feron, Olivier
通讯作者：
Feron, Olivier
影响因子：
158.5
作者：
Gogas, H;Ioannovich, J;Kirkwood, JM
通讯作者：
Kirkwood, JM
DOI：
10.4049/jimmunol.1001176
发表时间：
2010-08-15
期刊：
Journal of immunology (Baltimore, Md. : 1950)
影响因子：
--
作者：
Ferrer IR;Wagener ME;Robertson JM;Turner AP;Araki K;Ahmed R;Kirk AD;Larsen CP;Ford ML
通讯作者：
Ford ML
PD-L1 的过度表达与人类肝细胞癌的肿瘤侵袭性和术后复发显着相关。
影响因子：
11.5
作者：
Gao, Qiang;Wang, Xiao-Ying;Fan, Jia
通讯作者：
Fan, Jia
影响因子：
20.3
作者：
Aggarwal, S;Pittenger, MF
通讯作者：
Pittenger, MF